ATXS 11.54 Astria Therapeutics, Inc.
| Range: | 4.26-16.9 | Vol Avg: | 354676 | Last Div: | 0 | Changes: | 1.12 |
| Beta: | 0.71 | Cap: | 0.66B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jun 25 2015 | Empoloyees: | 59 | ||
| CUSIP: | 04635X102 | CIK: | 0001454789 | ISIN: | US04635X1028 | Country: | US |
| CEO: | Ms. Jill C. Milne Ph.D. | Website: | https://www.astriatx.com | ||||
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Stock Details
ATXS 25
Astria Therapeutics price target lowered to $25 from $29 at Oppenheimer
Hartaj Singh·Tue May 21 2024
Oppenheimer
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow